Eosinophilic Granulomatosis with Polyangiitis Relapse after COVID-19 Vaccination: A Case Report

Background: We here describe the case of a 71-year-old Caucasian woman previously diagnosed with Eosinophilic Granulomatosis with Polyangiitis (EGPA) that had been treated with Mepolizumab, an anti-IL5 monoclonal antibody, since 2019 with a good clinical response. Methods: She had a mild COVID-19 in December 2020 and she tested negative for SARS-CoV-2 infection in only late January 2021. In April 2021 she received the first dose of mRNA BNT162b2 vaccine. Ten days later she developed myalgia, dyspnea and numbness of the limbs due to a relapse of EGPA that occurred during Mepolizumab treatment.

Automated summary

This is a case report of a 71-year-old Caucasian woman with Eosinophilic Granulomatosis with Polyangiitis (EGPA). She had been treated with Mepolizumab since 2019 and had a good clinical response. In December 2020, she had a mild COVID-19 and tested negative for SARS-CoV-2 infection in late January 2021. After receiving the first dose of mRNA BNT162b2 vaccine in April 2021, she experienced a relapse of EGPA with symptoms of myalgia, dyspnea and limb numbness.